HaoTian Biotechnology (01877.HK) plans to invest 53.08 million yuan in Shanghai Zhiyu Biopharmaceuticals with patented equipment to layout ADC and multi-specific antibody research and development.

Zhaitong Financial News APP reported that Genetimes Bio (01877.HK) announced that the company intends to enter into a joint venture agreement with Suzhou Zhonghe, Genetimes Engineering, Suzhou Junmeng, and Dr. Yao Sheng, to establish a joint venture company Shanghai Zhiyu Biopharmaceutical Co., Ltd. The transferor (the company, Suzhou Zhonghe, Genetimes Engineering, and Suzhou Junmeng) conditionally agreed to (i) grant a license to the joint venture company for certain licensed intellectual property rights for research, development, manufacturing, use, and commercialization of licensed products; (ii) transfer tangible assets to the joint venture company; and (iii) transfer IP rights to the joint venture company. In consideration for the above, the consideration amount is approximately RMB 53.08 million, and the joint venture company will issue RMB 250,000 of new registered capital to the company.